|
시장보고서
상품코드
2055220
유전자 침묵 시장 : 유형별, 구성요소별, 용도별, 치료 영역별, 기술별, 전달 방법별, 최종사용자별, 지역별Gene Silencing Market, By Type, By Component, By Application, By Therapeutic Area, By Technology, By Delivery Method, By End User, By Geography |
||||||
유전자 침묵 시장은 2026년에 127억 9,000만 달러로 추정되며, 2033년까지 322억 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 14.1%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 127억 9,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 14.10% | 2033년 시장 규모 예측 : | 322억 달러 |
세계 유전자 침묵 시장은 생명공학 및 제약 업계에서 급속히 발전하고 있는 분야로, 특정 유전자를 표적으로 삼아 그 발현을 조절하는 혁신적인 치료 접근법을 포함하고 있습니다. 유전자 침묵은 RNA 간섭(RNAi) 또는 유전자 노크다운이라고도 불리며, 소간섭 RNA(siRNA), 마이크로 RNA(miRNA), 안티센스 올리고뉴클레오티드, CRISPR 기반 기술 등 다양한 연구 기법을 통해 표적 유전자의 발현을 차단하거나 억제하는 고도의 분자적 메커니즘을 수반합니다.
이 시장은 정밀의료 접근법이 필요한 유전성 질환, 암, 심혈관 질환, 신경계 질환의 유병률 증가에 힘입어 큰 성장세를 보이고 있습니다. 이 기술은 오프타겟 효과를 최소화하면서 질병의 원인이 되는 유전자를 특이적으로 침묵시킴으로써, 기존에는 치료가 어려웠던 표적에 대한 치료에 전례 없는 기회를 제공합니다. 대형 제약사, 생명공학 기업 및 연구 기관들은 차세대 치료제를 개발하기 위해 유전자 침묵 플랫폼에 막대한 투자를 하고 있습니다. 이 시장에는 유전자 침묵제의 안정성과 생체 이용률을 높이는 지질 나노입자, 바이러스 벡터, 그리고 접합체 기반의 전달 메커니즘을 포함한 다양한 전달 시스템이 포함됩니다. 규제 체계가 지속적으로 발전하고 이러한 혁신적인 치료법을 뒷받침함에 따라, 유전자 침묵 시장은 여러 치료 분야에서 치료 패러다임을 혁신하고, 막대한 상업적 기회를 창출하며, 전 세계적으로 중요한 미충족 의료 수요를 해결할 수 있는 위치에 있습니다.
시장 역학
세계 유전자 침묵 시장은 전 세계 유전성 질환 및 만성 질환의 유병률 증가 등 몇 가지 강력한 시장 성장 촉진요인에 힘입어 성장하고 있습니다. 이에 따라, 질병의 원인이 되는 유전자를 특이적으로 조절할 수 있는 표적 치료법에 대한 수요가 크게 증가하고 있습니다. 파티실란이나 기보실란과 같은 승인된 RNAi 치료제의 성공 사례가 증가하고 있는 것은 유전자 침묵 기술의 임상적 잠재력을 입증하는 것이며, 제약 업계 전반의 투자와 개발 활동을 촉진하고 있습니다. 전달 시스템, 특히 리포좀 및 조직 특이적 표적화 메커니즘 분야의 기술적 진보로 인해 치료 효과가 크게 향상되고 부작용이 경감됨에 따라, 유전자 침묵화 접근법은 임상 적용 측면에서 더욱 실현 가능한 방법이 되었습니다. 그러나 시장에는 유전자 침묵 치료법에 수반되는 높은 개발 비용, 전문 시설과 전문 지식을 필요로 하는 복잡한 제조 공정, 개발 기간을 연장하고 기업의 재무적 위험을 높이는 엄격한 규제 요건 등 뚜렷한 제약 요인이 존재합니다.
또한, 오프타겟 효과, 면역원성에 대한 우려, 그리고 특정 조직으로의 전달 효율과 관련된 문제들은 여전히 기술의 광범위한 보급을 가로막는 기술적 장벽으로 남아 있습니다. 이러한 제약이 있음에도 불구하고, 희귀질환을 넘어 심혈관 질환, 대사성 질환, 종양학 분야 등 보다 일반적인 질환으로의 응용이 확대됨에 따라 큰 기회가 생겨나고 있습니다. 맞춤형 의료와 정밀의료에 대한 관심이 높아지고 있는 것은 유전자 침묵 기술에 유리한 환경을 조성하고 있으며, 한편 제약 회사와 생명공학 기업 간의 협력 강화는 지식 공유를 촉진하고 제품 개발을 가속화하고 있습니다. 또한, 신흥 시장에서는 의료 인프라가 개선되고 혁신적인 치료법에 대한 규제 체계가 점차 확립되고 있어 미개척 잠재력이 존재하며, 이에 따라 유전자 침묵 시장은 다양한 치료 분야에서 지속적인 성장과 혁신을 실현할 수 있는 위치에 있습니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 주요 지표를 바탕으로 전 세계 유전자 침묵화 시장의 주요 기업 프로파일을 작성했습니다. 기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적 및 전략.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 세계 유전자 침묵화 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 유전자 침묵화 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 유전자 침묵 시장 : 유형별, 2021년-2033년
제5장 세계의 유전자 침묵 시장 : 컴포넌트별, 2021년-2033년
제6장 세계의 유전자 침묵 시장 : 용도별, 2021년-2033년
제7장 세계의 유전자 침묵 시장 : 치료 영역별, 2021년-2033년
제8장 세계의 유전자 침묵 시장 : 기술별, 2021년-2033년
제9장 세계의 유전자 침묵 시장 : 전달 방법별, 2021년-2033년
제10장 세계의 유전자 침묵 시장 : 최종사용자별, 2021년-2033년
제11장 세계의 유전자 침묵 시장 : 지역별, 2021년-2033년
제12장 경쟁 구도
제13장 애널리스트의 제안
제14장 참고 문헌 및 조사 방법
LSH 26.06.22Gene Silencing Market is estimated to be valued at USD 12.79 Bn in 2026 and is expected to reach USD 32.20 Bn by 2033, growing at a compound annual growth rate (CAGR) of 14.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 12.79 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 14.10% | 2033 Value Projection: | USD 32.20 Bn |
The global gene silencing market represents a rapidly evolving segment within the biotechnology and pharmaceutical industries, encompassing innovative therapeutic approaches that target specific genes to modulate their expression. Gene silencing, also known as RNA interference (RNAi) or gene knockdown, involves sophisticated molecular mechanisms that prevent or reduce the expression of target genes through various methodologies including small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides, and CRISPR-based technologies.
This market has gained substantial momentum due to increasing prevalence of genetic disorders, cancer, cardiovascular diseases, and neurological conditions that require precision medicine approaches. The technology offers unprecedented opportunities for treating previously undruggable targets by specifically silencing disease-causing genes while minimizing off-target effects. Major pharmaceutical companies, biotechnology firms, and research institutions are heavily investing in gene silencing platforms to develop next-generation therapeutics. The market encompasses various delivery systems including lipid nanoparticles, viral vectors, and conjugate-based delivery mechanisms that enhance the stability and bioavailability of gene silencing agents. As regulatory frameworks continue to evolve and support these innovative therapies, the gene silencing market is positioned to transform treatment paradigms across multiple therapeutic areas, driving significant commercial opportunities and addressing critical unmet medical needs globally.
Market Dynamics
The global gene silencing market is propelled by several compelling drivers, including the escalating prevalence of genetic disorders and chronic diseases worldwide, which creates substantial demand for targeted therapeutic interventions that can specifically modulate disease-causing genes. The increasing success of approved RNAi therapeutics such as patisiran and givosiran has validated the clinical potential of gene silencing technologies, encouraging greater investment and development activities across the pharmaceutical industry. Technological advancements in delivery systems, particularly lipid nanoparticles and tissue-specific targeting mechanisms, have significantly improved the therapeutic efficacy and reduced adverse effects, making gene silencing approaches more viable for clinical applications. However, the market faces notable restraints including high development costs associated with gene silencing therapies, complex manufacturing processes requiring specialized facilities and expertise, and stringent regulatory requirements that extend development timelines and increase financial risks for companies.
Additionally, challenges related to off-target effects, immunogenicity concerns, and delivery efficiency to specific tissues continue to pose technical barriers for widespread adoption. Despite these constraints, substantial opportunities emerge from expanding applications beyond rare diseases into more prevalent conditions such as cardiovascular diseases, metabolic disorders, and oncology indications. The growing emphasis on personalized medicine and precision therapeutics creates favorable conditions for gene silencing technologies, while increasing collaborations between pharmaceutical companies and biotechnology firms facilitate knowledge sharing and accelerate product development. Furthermore, emerging markets present untapped potential as healthcare infrastructure improves and regulatory pathways for innovative therapies become more established, positioning the gene silencing market for sustained growth and innovation across diverse therapeutic landscapes.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global gene silencing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Danaher Corporation, Bio Rad Laboratories Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Silence Therapeutics plc, Dicerna Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arbutus Biopharma Corporation, Wave Life Sciences Ltd., Moderna Inc., and BioNTech SE
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global gene silencing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gene silencing market
Market Segmentation
- Type Insights (Revenue, USD Bn, 2021 - 2033)
- Post-Transcriptional
- Transcriptional
- Component Insights (Revenue, USD Bn, 2021 - 2033)
- Product (Reagents, Kits, Instruments)
- Services
- Application Insights (Revenue, USD Bn, 2021 - 2033)
- Functional Genomics
- Drug Target Validation
- Disease Modeling
- Therapeutic Development
- Bioproduction Optimization
- Therapeutic Area Insights (Revenue, USD Bn, 2021 - 2033)
- Oncology
- Genetic Disorders
- Infectious Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Metabolic Disorders
- Autoimmune Disorders
- Ophthalmic Diseases
- Technology Insights (Revenue, USD Bn, 2021 - 2033)
- RNA Interference (RNAi)
- Antisense Oligonucleotides (ASOs)
- CRISPR-based Gene Silencing
- siRNA
- shRNA
- miRNA
- DNA Methylation-based Silencing
- Histone Modification-based Silencing
- Delivery Method Insights (Revenue, USD Bn, 2021 - 2033)
- Viral Vector Delivery
- Non-Viral Vector Delivery
- Lipid Nanoparticles
- Electroporation
- Physical Methods (Microinjection, Gene Gun, Ultrasound)
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Pharmaceutical and Biotech Companies
- Academic and Research Institutes
- Contract Research Organizations (CROs)
- Diagnostic Laboratories
- Government and Non-Profit Research Bodies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Agilent Technologies Inc.
- Danaher Corporation
- Bio Rad Laboratories Inc.
- Alnylam Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- Silence Therapeutics plc
- Dicerna Pharmaceuticals Inc.
- Sarepta Therapeutics Inc.
- Arbutus Biopharma Corporation
- Wave Life Sciences Ltd.
- Moderna Inc.
- BioNTech SE
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Gene Silencing Market, By Type
- Global Gene Silencing Market, By Component
- Global Gene Silencing Market, By Application
- Global Gene Silencing Market, By Therapeutic Area
- Global Gene Silencing Market, By Technology
- Global Gene Silencing Market, By Delivery Method
- Global Gene Silencing Market, By End User
- Global Gene Silencing Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Gene Silencing Market, By Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Post-Transcriptional
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Transcriptional
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Gene Silencing Market, By Component, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Product (Reagents, Kits, Instruments)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Gene Silencing Market, By Application, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Functional Genomics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Drug Target Validation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Disease Modeling
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Therapeutic Development
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Bioproduction Optimization
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Gene Silencing Market, By Therapeutic Area, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Metabolic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Autoimmune Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ophthalmic Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Gene Silencing Market, By Technology, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- RNA Interference (RNAi)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Antisense Oligonucleotides (ASOs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- CRISPR-based Gene Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- siRNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- shRNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- miRNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- DNA Methylation-based Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Histone Modification-based Silencing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Gene Silencing Market, By Delivery Method, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Viral Vector Delivery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Non-Viral Vector Delivery
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Lipid Nanoparticles
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Electroporation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Physical Methods (Microinjection, Gene Gun, Ultrasound)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Gene Silencing Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pharmaceutical and Biotech Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Government and Non-Profit Research Bodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Gene Silencing Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Delivery Method, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Thermo Fisher Scientific Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Agilent Technologies Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Danaher Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bio Rad Laboratories Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alnylam Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ionis Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Arrowhead Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Silence Therapeutics plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dicerna Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sarepta Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Arbutus Biopharma Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Wave Life Sciences Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Moderna Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BioNTech SE
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
